Two weeks after their bid failed to garner key support from shareholders, Stada’s wannabe buyers are back.
London-based private equity firm Cinven and Boston investment firm Bain Capital have returned with plans to resubmit their takeover offer for the German drugmaker, but this time, they’re sweetening the deal. The partners are offering €66.25 per Stada share, an improvement of about €16 million on their shot-down €5.32 billion buyout bid.
While it’s normally not that easy for suitors to come back with a new offer, Germany’s takeover authorities have excused Bain and Cinven from the customary 1-year exclusion period with Stada’s consent. The German drugmaker said it supports the new bid, with newly minted interim CEO Engelbert Coster Tjeenk Willink telling shareholders in a statement that “enabling Bain Capital and Cinven to submit an improved offer is in the best interest of the company and our shareholders.”
“The improvements in the form of financial consideration and the commitments to our employees, our locations and our corporate strategy are showing us that Bain Capital and Cinven are highly interested in developing Stada together with us,” he added.
This time around, it’ll also be easier to usher the bid past investors, just 63% of whom will need to OK the transaction for it to move forward. The last bid came along with a minimum acceptance threshold of 67.5%, and just 65.52% came out in favor of the deal.
While Stada initially touted the turnout as proof that investors liked its current tack, the company’s board quickly replaced its CEO Matthias Wiedenfels and CFO Helmut Kraft with Willink and Bernhard Düttmann, respectively. And Reuters’ sources posited that the lack of deal enthusiasm was more a product of inaction on the part of retail investors than anything else.
Either way, the transaction should now have an easier time passing the bar, meaning a months-long deal saga could finally have its end in sight. Bain and Cinven notched their original offer back in April, following a $3.7 billion bid from Boston-based private equity firm Advent International and rumors that companies ranging from Mylan to China’s Fosun Pharmaceutical could be weighing their own offers.
By Carly Helfand
Source: Fierce Pharma
Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.
Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.
On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.